nodes	percent_of_prediction	percent_of_DWPC	metapath
Azacitidine—Nucleic Acid Synthesis Inhibitors—Azathioprine—systemic scleroderma	0.862	1	CiPCiCtD
Azacitidine—DNMT3A—connective tissue—systemic scleroderma	0.00258	0.144	CbGeAlD
Azacitidine—DNMT3A—skin of body—systemic scleroderma	0.00233	0.13	CbGeAlD
Azacitidine—DNMT3A—digestive system—systemic scleroderma	0.00187	0.104	CbGeAlD
Azacitidine—DNMT3A—tendon—systemic scleroderma	0.00178	0.0991	CbGeAlD
Azacitidine—CDA—tendon—systemic scleroderma	0.00168	0.0937	CbGeAlD
Azacitidine—DNMT1—connective tissue—systemic scleroderma	0.00156	0.0872	CbGeAlD
Azacitidine—DNMT3A—lung—systemic scleroderma	0.00156	0.087	CbGeAlD
Azacitidine—DNMT1—skin of body—systemic scleroderma	0.00141	0.0788	CbGeAlD
Azacitidine—DNMT1—digestive system—systemic scleroderma	0.00113	0.063	CbGeAlD
Azacitidine—DNMT1—tendon—systemic scleroderma	0.00107	0.06	CbGeAlD
Azacitidine—Glucosamine—MMP9—systemic scleroderma	0.000959	1	CrCbGaD
Azacitidine—DNMT1—lung—systemic scleroderma	0.000942	0.0526	CbGeAlD
Azacitidine—DNMT3A—Amcinonide—Mometasone—systemic scleroderma	0.000728	0.257	CbGdCrCtD
Azacitidine—DNMT3A—Amcinonide—Prednisone—systemic scleroderma	0.000397	0.14	CbGdCrCtD
Azacitidine—DNMT1—Budesonide—Mometasone—systemic scleroderma	0.000288	0.102	CbGdCrCtD
Azacitidine—DNMT3A—Betamethasone—Mometasone—systemic scleroderma	0.000232	0.082	CbGdCrCtD
Azacitidine—DNMT3A—Dexamethasone—Mometasone—systemic scleroderma	0.000232	0.082	CbGdCrCtD
Azacitidine—DNMT1—Betamethasone—Mometasone—systemic scleroderma	0.000176	0.0622	CbGdCrCtD
Azacitidine—DNMT1—Dexamethasone—Mometasone—systemic scleroderma	0.000176	0.0622	CbGdCrCtD
Azacitidine—DNMT1—Budesonide—Prednisone—systemic scleroderma	0.000157	0.0554	CbGdCrCtD
Azacitidine—DNMT3A—Dexamethasone—Prednisone—systemic scleroderma	0.000127	0.0447	CbGdCrCtD
Azacitidine—DNMT3A—Betamethasone—Prednisone—systemic scleroderma	0.000127	0.0447	CbGdCrCtD
Azacitidine—DNMT1—Dexamethasone—Prednisone—systemic scleroderma	9.6e-05	0.0339	CbGdCrCtD
Azacitidine—DNMT1—Betamethasone—Prednisone—systemic scleroderma	9.6e-05	0.0339	CbGdCrCtD
Azacitidine—Hyperhidrosis—Lisinopril—systemic scleroderma	7.88e-05	0.000675	CcSEcCtD
Azacitidine—Diarrhoea—Captopril—systemic scleroderma	7.88e-05	0.000675	CcSEcCtD
Azacitidine—Decreased appetite—Mycophenolic acid—systemic scleroderma	7.87e-05	0.000674	CcSEcCtD
Azacitidine—Syncope—Mycophenolate mofetil—systemic scleroderma	7.85e-05	0.000673	CcSEcCtD
Azacitidine—Leukopenia—Mycophenolate mofetil—systemic scleroderma	7.84e-05	0.000671	CcSEcCtD
Azacitidine—Feeling abnormal—Leflunomide—systemic scleroderma	7.82e-05	0.00067	CcSEcCtD
Azacitidine—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	7.82e-05	0.00067	CcSEcCtD
Azacitidine—Fatigue—Mycophenolic acid—systemic scleroderma	7.8e-05	0.000669	CcSEcCtD
Azacitidine—Nausea—Mometasone—systemic scleroderma	7.79e-05	0.000667	CcSEcCtD
Azacitidine—Anorexia—Lisinopril—systemic scleroderma	7.77e-05	0.000666	CcSEcCtD
Azacitidine—Gastrointestinal pain—Leflunomide—systemic scleroderma	7.76e-05	0.000665	CcSEcCtD
Azacitidine—Pain—Mycophenolic acid—systemic scleroderma	7.74e-05	0.000663	CcSEcCtD
Azacitidine—Constipation—Mycophenolic acid—systemic scleroderma	7.74e-05	0.000663	CcSEcCtD
Azacitidine—Weight decreased—Prednisone—systemic scleroderma	7.7e-05	0.00066	CcSEcCtD
Azacitidine—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	7.69e-05	0.000659	CcSEcCtD
Azacitidine—Cough—Mycophenolate mofetil—systemic scleroderma	7.64e-05	0.000655	CcSEcCtD
Azacitidine—Hypotension—Lisinopril—systemic scleroderma	7.62e-05	0.000653	CcSEcCtD
Azacitidine—Dizziness—Captopril—systemic scleroderma	7.61e-05	0.000652	CcSEcCtD
Azacitidine—Convulsion—Mycophenolate mofetil—systemic scleroderma	7.58e-05	0.00065	CcSEcCtD
Azacitidine—Depression—Prednisone—systemic scleroderma	7.57e-05	0.000649	CcSEcCtD
Azacitidine—Hypertension—Mycophenolate mofetil—systemic scleroderma	7.56e-05	0.000648	CcSEcCtD
Azacitidine—Urticaria—Leflunomide—systemic scleroderma	7.54e-05	0.000646	CcSEcCtD
Azacitidine—Abdominal pain—Leflunomide—systemic scleroderma	7.5e-05	0.000643	CcSEcCtD
Azacitidine—Body temperature increased—Leflunomide—systemic scleroderma	7.5e-05	0.000643	CcSEcCtD
Azacitidine—Feeling abnormal—Mycophenolic acid—systemic scleroderma	7.46e-05	0.000639	CcSEcCtD
Azacitidine—Chest pain—Mycophenolate mofetil—systemic scleroderma	7.45e-05	0.000639	CcSEcCtD
Azacitidine—Myalgia—Mycophenolate mofetil—systemic scleroderma	7.45e-05	0.000639	CcSEcCtD
Azacitidine—Arthralgia—Mycophenolate mofetil—systemic scleroderma	7.45e-05	0.000639	CcSEcCtD
Azacitidine—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	7.43e-05	0.000637	CcSEcCtD
Azacitidine—Anxiety—Mycophenolate mofetil—systemic scleroderma	7.43e-05	0.000636	CcSEcCtD
Azacitidine—Hypersensitivity—Azathioprine—systemic scleroderma	7.4e-05	0.000634	CcSEcCtD
Azacitidine—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	7.4e-05	0.000634	CcSEcCtD
Azacitidine—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	7.4e-05	0.000634	CcSEcCtD
Azacitidine—Insomnia—Lisinopril—systemic scleroderma	7.37e-05	0.000632	CcSEcCtD
Azacitidine—Discomfort—Mycophenolate mofetil—systemic scleroderma	7.36e-05	0.000631	CcSEcCtD
Azacitidine—Vomiting—Captopril—systemic scleroderma	7.32e-05	0.000627	CcSEcCtD
Azacitidine—Dyspnoea—Lisinopril—systemic scleroderma	7.27e-05	0.000623	CcSEcCtD
Azacitidine—Rash—Captopril—systemic scleroderma	7.26e-05	0.000622	CcSEcCtD
Azacitidine—Dermatitis—Captopril—systemic scleroderma	7.25e-05	0.000621	CcSEcCtD
Azacitidine—Headache—Captopril—systemic scleroderma	7.21e-05	0.000618	CcSEcCtD
Azacitidine—Confusional state—Mycophenolate mofetil—systemic scleroderma	7.2e-05	0.000617	CcSEcCtD
Azacitidine—Dyspepsia—Lisinopril—systemic scleroderma	7.18e-05	0.000615	CcSEcCtD
Azacitidine—Body temperature increased—Mycophenolic acid—systemic scleroderma	7.16e-05	0.000613	CcSEcCtD
Azacitidine—Abdominal pain—Mycophenolic acid—systemic scleroderma	7.16e-05	0.000613	CcSEcCtD
Azacitidine—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	7.14e-05	0.000612	CcSEcCtD
Azacitidine—Oedema—Mycophenolate mofetil—systemic scleroderma	7.14e-05	0.000612	CcSEcCtD
Azacitidine—Infection—Mycophenolate mofetil—systemic scleroderma	7.1e-05	0.000608	CcSEcCtD
Azacitidine—Decreased appetite—Lisinopril—systemic scleroderma	7.09e-05	0.000607	CcSEcCtD
Azacitidine—Gastrointestinal disorder—Lisinopril—systemic scleroderma	7.04e-05	0.000603	CcSEcCtD
Azacitidine—Fatigue—Lisinopril—systemic scleroderma	7.03e-05	0.000602	CcSEcCtD
Azacitidine—Shock—Mycophenolate mofetil—systemic scleroderma	7.03e-05	0.000602	CcSEcCtD
Azacitidine—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	7.01e-05	0.0006	CcSEcCtD
Azacitidine—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	6.99e-05	0.000599	CcSEcCtD
Azacitidine—Hypersensitivity—Leflunomide—systemic scleroderma	6.99e-05	0.000599	CcSEcCtD
Azacitidine—Constipation—Lisinopril—systemic scleroderma	6.97e-05	0.000597	CcSEcCtD
Azacitidine—Pain—Lisinopril—systemic scleroderma	6.97e-05	0.000597	CcSEcCtD
Azacitidine—Tachycardia—Mycophenolate mofetil—systemic scleroderma	6.97e-05	0.000597	CcSEcCtD
Azacitidine—Skin disorder—Mycophenolate mofetil—systemic scleroderma	6.94e-05	0.000595	CcSEcCtD
Azacitidine—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	6.91e-05	0.000592	CcSEcCtD
Azacitidine—Diarrhoea—Azathioprine—systemic scleroderma	6.88e-05	0.000589	CcSEcCtD
Azacitidine—Haemoglobin—Prednisone—systemic scleroderma	6.85e-05	0.000587	CcSEcCtD
Azacitidine—Nausea—Captopril—systemic scleroderma	6.84e-05	0.000586	CcSEcCtD
Azacitidine—Haemorrhage—Prednisone—systemic scleroderma	6.82e-05	0.000584	CcSEcCtD
Azacitidine—Anorexia—Mycophenolate mofetil—systemic scleroderma	6.81e-05	0.000584	CcSEcCtD
Azacitidine—Asthenia—Leflunomide—systemic scleroderma	6.81e-05	0.000583	CcSEcCtD
Azacitidine—Pancytopenia—Methotrexate—systemic scleroderma	6.76e-05	0.000579	CcSEcCtD
Azacitidine—Feeling abnormal—Lisinopril—systemic scleroderma	6.72e-05	0.000576	CcSEcCtD
Azacitidine—Pruritus—Leflunomide—systemic scleroderma	6.71e-05	0.000575	CcSEcCtD
Azacitidine—Connective tissue disorder—Prednisone—systemic scleroderma	6.7e-05	0.000574	CcSEcCtD
Azacitidine—Hypotension—Mycophenolate mofetil—systemic scleroderma	6.68e-05	0.000572	CcSEcCtD
Azacitidine—Gastrointestinal pain—Lisinopril—systemic scleroderma	6.67e-05	0.000571	CcSEcCtD
Azacitidine—Neutropenia—Methotrexate—systemic scleroderma	6.65e-05	0.00057	CcSEcCtD
Azacitidine—Dysuria—Methotrexate—systemic scleroderma	6.65e-05	0.00057	CcSEcCtD
Azacitidine—Dizziness—Azathioprine—systemic scleroderma	6.64e-05	0.000569	CcSEcCtD
Azacitidine—Upper respiratory tract infection—Methotrexate—systemic scleroderma	6.61e-05	0.000567	CcSEcCtD
Azacitidine—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	6.51e-05	0.000558	CcSEcCtD
Azacitidine—Asthenia—Mycophenolic acid—systemic scleroderma	6.5e-05	0.000557	CcSEcCtD
Azacitidine—Diarrhoea—Leflunomide—systemic scleroderma	6.49e-05	0.000556	CcSEcCtD
Azacitidine—Urticaria—Lisinopril—systemic scleroderma	6.48e-05	0.000555	CcSEcCtD
Azacitidine—Insomnia—Mycophenolate mofetil—systemic scleroderma	6.46e-05	0.000554	CcSEcCtD
Azacitidine—Abdominal pain—Lisinopril—systemic scleroderma	6.45e-05	0.000552	CcSEcCtD
Azacitidine—Body temperature increased—Lisinopril—systemic scleroderma	6.45e-05	0.000552	CcSEcCtD
Azacitidine—Pruritus—Mycophenolic acid—systemic scleroderma	6.4e-05	0.000549	CcSEcCtD
Azacitidine—Vomiting—Azathioprine—systemic scleroderma	6.39e-05	0.000547	CcSEcCtD
Azacitidine—Pneumonia—Methotrexate—systemic scleroderma	6.38e-05	0.000547	CcSEcCtD
Azacitidine—Eye disorder—Prednisone—systemic scleroderma	6.37e-05	0.000546	CcSEcCtD
Azacitidine—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	6.37e-05	0.000546	CcSEcCtD
Azacitidine—Infestation—Methotrexate—systemic scleroderma	6.35e-05	0.000544	CcSEcCtD
Azacitidine—Infestation NOS—Methotrexate—systemic scleroderma	6.35e-05	0.000544	CcSEcCtD
Azacitidine—Rash—Azathioprine—systemic scleroderma	6.34e-05	0.000543	CcSEcCtD
Azacitidine—Dermatitis—Azathioprine—systemic scleroderma	6.33e-05	0.000542	CcSEcCtD
Azacitidine—Depression—Methotrexate—systemic scleroderma	6.33e-05	0.000542	CcSEcCtD
Azacitidine—Headache—Azathioprine—systemic scleroderma	6.29e-05	0.000539	CcSEcCtD
Azacitidine—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	6.29e-05	0.000539	CcSEcCtD
Azacitidine—Dizziness—Leflunomide—systemic scleroderma	6.28e-05	0.000538	CcSEcCtD
Azacitidine—Renal failure—Methotrexate—systemic scleroderma	6.24e-05	0.000535	CcSEcCtD
Azacitidine—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	6.21e-05	0.000532	CcSEcCtD
Azacitidine—Diarrhoea—Mycophenolic acid—systemic scleroderma	6.19e-05	0.000531	CcSEcCtD
Azacitidine—Stomatitis—Methotrexate—systemic scleroderma	6.19e-05	0.00053	CcSEcCtD
Azacitidine—Angiopathy—Prednisone—systemic scleroderma	6.18e-05	0.00053	CcSEcCtD
Azacitidine—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	6.17e-05	0.000529	CcSEcCtD
Azacitidine—Immune system disorder—Prednisone—systemic scleroderma	6.16e-05	0.000528	CcSEcCtD
Azacitidine—Pain—Mycophenolate mofetil—systemic scleroderma	6.11e-05	0.000524	CcSEcCtD
Azacitidine—Constipation—Mycophenolate mofetil—systemic scleroderma	6.11e-05	0.000524	CcSEcCtD
Azacitidine—Haematuria—Methotrexate—systemic scleroderma	6.05e-05	0.000518	CcSEcCtD
Azacitidine—Vomiting—Leflunomide—systemic scleroderma	6.03e-05	0.000517	CcSEcCtD
Azacitidine—Alopecia—Prednisone—systemic scleroderma	6.02e-05	0.000516	CcSEcCtD
Azacitidine—Hypersensitivity—Lisinopril—systemic scleroderma	6.01e-05	0.000515	CcSEcCtD
Azacitidine—Hepatobiliary disease—Methotrexate—systemic scleroderma	6e-05	0.000514	CcSEcCtD
Azacitidine—Dizziness—Mycophenolic acid—systemic scleroderma	5.99e-05	0.000513	CcSEcCtD
Azacitidine—Epistaxis—Methotrexate—systemic scleroderma	5.99e-05	0.000513	CcSEcCtD
Azacitidine—Rash—Leflunomide—systemic scleroderma	5.98e-05	0.000513	CcSEcCtD
Azacitidine—Dermatitis—Leflunomide—systemic scleroderma	5.98e-05	0.000512	CcSEcCtD
Azacitidine—Mental disorder—Prednisone—systemic scleroderma	5.97e-05	0.000512	CcSEcCtD
Azacitidine—Nausea—Azathioprine—systemic scleroderma	5.97e-05	0.000511	CcSEcCtD
Azacitidine—Headache—Leflunomide—systemic scleroderma	5.94e-05	0.000509	CcSEcCtD
Azacitidine—Malnutrition—Prednisone—systemic scleroderma	5.93e-05	0.000508	CcSEcCtD
Azacitidine—Erythema—Prednisone—systemic scleroderma	5.93e-05	0.000508	CcSEcCtD
Azacitidine—Agranulocytosis—Methotrexate—systemic scleroderma	5.92e-05	0.000507	CcSEcCtD
Azacitidine—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	5.89e-05	0.000504	CcSEcCtD
Azacitidine—Asthenia—Lisinopril—systemic scleroderma	5.85e-05	0.000501	CcSEcCtD
Azacitidine—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	5.84e-05	0.000501	CcSEcCtD
Azacitidine—Pruritus—Lisinopril—systemic scleroderma	5.77e-05	0.000494	CcSEcCtD
Azacitidine—Vomiting—Mycophenolic acid—systemic scleroderma	5.76e-05	0.000493	CcSEcCtD
Azacitidine—Haemoglobin—Methotrexate—systemic scleroderma	5.73e-05	0.000491	CcSEcCtD
Azacitidine—Rash—Mycophenolic acid—systemic scleroderma	5.71e-05	0.000489	CcSEcCtD
Azacitidine—Dermatitis—Mycophenolic acid—systemic scleroderma	5.7e-05	0.000489	CcSEcCtD
Azacitidine—Haemorrhage—Methotrexate—systemic scleroderma	5.7e-05	0.000488	CcSEcCtD
Azacitidine—Urticaria—Mycophenolate mofetil—systemic scleroderma	5.68e-05	0.000486	CcSEcCtD
Azacitidine—Headache—Mycophenolic acid—systemic scleroderma	5.67e-05	0.000486	CcSEcCtD
Azacitidine—Pharyngitis—Methotrexate—systemic scleroderma	5.65e-05	0.000484	CcSEcCtD
Azacitidine—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	5.65e-05	0.000484	CcSEcCtD
Azacitidine—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	5.65e-05	0.000484	CcSEcCtD
Azacitidine—Nausea—Leflunomide—systemic scleroderma	5.64e-05	0.000483	CcSEcCtD
Azacitidine—Urinary tract disorder—Methotrexate—systemic scleroderma	5.63e-05	0.000482	CcSEcCtD
Azacitidine—Urethral disorder—Methotrexate—systemic scleroderma	5.58e-05	0.000478	CcSEcCtD
Azacitidine—Diarrhoea—Lisinopril—systemic scleroderma	5.58e-05	0.000478	CcSEcCtD
Azacitidine—Ill-defined disorder—Prednisone—systemic scleroderma	5.51e-05	0.000472	CcSEcCtD
Azacitidine—Anaemia—Prednisone—systemic scleroderma	5.48e-05	0.00047	CcSEcCtD
Azacitidine—Dizziness—Lisinopril—systemic scleroderma	5.39e-05	0.000462	CcSEcCtD
Azacitidine—Nausea—Mycophenolic acid—systemic scleroderma	5.38e-05	0.000461	CcSEcCtD
Azacitidine—Malaise—Prednisone—systemic scleroderma	5.35e-05	0.000459	CcSEcCtD
Azacitidine—Eye disorder—Methotrexate—systemic scleroderma	5.32e-05	0.000456	CcSEcCtD
Azacitidine—Syncope—Prednisone—systemic scleroderma	5.32e-05	0.000456	CcSEcCtD
Azacitidine—Cardiac disorder—Methotrexate—systemic scleroderma	5.29e-05	0.000453	CcSEcCtD
Azacitidine—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	5.26e-05	0.000451	CcSEcCtD
Azacitidine—Loss of consciousness—Prednisone—systemic scleroderma	5.22e-05	0.000447	CcSEcCtD
Azacitidine—Vomiting—Lisinopril—systemic scleroderma	5.18e-05	0.000444	CcSEcCtD
Azacitidine—Angiopathy—Methotrexate—systemic scleroderma	5.17e-05	0.000443	CcSEcCtD
Azacitidine—Immune system disorder—Methotrexate—systemic scleroderma	5.15e-05	0.000441	CcSEcCtD
Azacitidine—Rash—Lisinopril—systemic scleroderma	5.14e-05	0.000441	CcSEcCtD
Azacitidine—Convulsion—Prednisone—systemic scleroderma	5.14e-05	0.000441	CcSEcCtD
Azacitidine—Dermatitis—Lisinopril—systemic scleroderma	5.14e-05	0.00044	CcSEcCtD
Azacitidine—Mediastinal disorder—Methotrexate—systemic scleroderma	5.13e-05	0.00044	CcSEcCtD
Azacitidine—Asthenia—Mycophenolate mofetil—systemic scleroderma	5.13e-05	0.000439	CcSEcCtD
Azacitidine—Hypertension—Prednisone—systemic scleroderma	5.12e-05	0.000439	CcSEcCtD
Azacitidine—Chills—Methotrexate—systemic scleroderma	5.11e-05	0.000438	CcSEcCtD
Azacitidine—Headache—Lisinopril—systemic scleroderma	5.11e-05	0.000438	CcSEcCtD
Azacitidine—Pruritus—Mycophenolate mofetil—systemic scleroderma	5.05e-05	0.000433	CcSEcCtD
Azacitidine—Myalgia—Prednisone—systemic scleroderma	5.05e-05	0.000433	CcSEcCtD
Azacitidine—Arthralgia—Prednisone—systemic scleroderma	5.05e-05	0.000433	CcSEcCtD
Azacitidine—Anxiety—Prednisone—systemic scleroderma	5.03e-05	0.000431	CcSEcCtD
Azacitidine—Alopecia—Methotrexate—systemic scleroderma	5.03e-05	0.000431	CcSEcCtD
Azacitidine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	5.02e-05	0.00043	CcSEcCtD
Azacitidine—Discomfort—Prednisone—systemic scleroderma	4.99e-05	0.000428	CcSEcCtD
Azacitidine—Mental disorder—Methotrexate—systemic scleroderma	4.99e-05	0.000428	CcSEcCtD
Azacitidine—Malnutrition—Methotrexate—systemic scleroderma	4.96e-05	0.000425	CcSEcCtD
Azacitidine—Erythema—Methotrexate—systemic scleroderma	4.96e-05	0.000425	CcSEcCtD
Azacitidine—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	4.89e-05	0.000419	CcSEcCtD
Azacitidine—Nausea—Lisinopril—systemic scleroderma	4.84e-05	0.000415	CcSEcCtD
Azacitidine—Anaphylactic shock—Prednisone—systemic scleroderma	4.84e-05	0.000415	CcSEcCtD
Azacitidine—Oedema—Prednisone—systemic scleroderma	4.84e-05	0.000415	CcSEcCtD
Azacitidine—Infection—Prednisone—systemic scleroderma	4.81e-05	0.000412	CcSEcCtD
Azacitidine—Back pain—Methotrexate—systemic scleroderma	4.8e-05	0.000411	CcSEcCtD
Azacitidine—Shock—Prednisone—systemic scleroderma	4.76e-05	0.000408	CcSEcCtD
Azacitidine—Nervous system disorder—Prednisone—systemic scleroderma	4.75e-05	0.000407	CcSEcCtD
Azacitidine—Tachycardia—Prednisone—systemic scleroderma	4.73e-05	0.000405	CcSEcCtD
Azacitidine—Dizziness—Mycophenolate mofetil—systemic scleroderma	4.72e-05	0.000405	CcSEcCtD
Azacitidine—Skin disorder—Prednisone—systemic scleroderma	4.7e-05	0.000403	CcSEcCtD
Azacitidine—Hyperhidrosis—Prednisone—systemic scleroderma	4.68e-05	0.000401	CcSEcCtD
Azacitidine—Anorexia—Prednisone—systemic scleroderma	4.62e-05	0.000396	CcSEcCtD
Azacitidine—Ill-defined disorder—Methotrexate—systemic scleroderma	4.6e-05	0.000394	CcSEcCtD
Azacitidine—Anaemia—Methotrexate—systemic scleroderma	4.58e-05	0.000393	CcSEcCtD
Azacitidine—Vomiting—Mycophenolate mofetil—systemic scleroderma	4.54e-05	0.000389	CcSEcCtD
Azacitidine—Rash—Mycophenolate mofetil—systemic scleroderma	4.5e-05	0.000386	CcSEcCtD
Azacitidine—Dermatitis—Mycophenolate mofetil—systemic scleroderma	4.5e-05	0.000386	CcSEcCtD
Azacitidine—Headache—Mycophenolate mofetil—systemic scleroderma	4.48e-05	0.000384	CcSEcCtD
Azacitidine—Malaise—Methotrexate—systemic scleroderma	4.47e-05	0.000383	CcSEcCtD
Azacitidine—Leukopenia—Methotrexate—systemic scleroderma	4.44e-05	0.00038	CcSEcCtD
Azacitidine—Musculoskeletal discomfort—Prednisone—systemic scleroderma	4.41e-05	0.000378	CcSEcCtD
Azacitidine—Insomnia—Prednisone—systemic scleroderma	4.38e-05	0.000375	CcSEcCtD
Azacitidine—Cough—Methotrexate—systemic scleroderma	4.33e-05	0.000371	CcSEcCtD
Azacitidine—Convulsion—Methotrexate—systemic scleroderma	4.3e-05	0.000368	CcSEcCtD
Azacitidine—Dyspepsia—Prednisone—systemic scleroderma	4.26e-05	0.000365	CcSEcCtD
Azacitidine—Nausea—Mycophenolate mofetil—systemic scleroderma	4.24e-05	0.000364	CcSEcCtD
Azacitidine—Chest pain—Methotrexate—systemic scleroderma	4.22e-05	0.000362	CcSEcCtD
Azacitidine—Arthralgia—Methotrexate—systemic scleroderma	4.22e-05	0.000362	CcSEcCtD
Azacitidine—Myalgia—Methotrexate—systemic scleroderma	4.22e-05	0.000362	CcSEcCtD
Azacitidine—Decreased appetite—Prednisone—systemic scleroderma	4.21e-05	0.000361	CcSEcCtD
Azacitidine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	4.19e-05	0.000359	CcSEcCtD
Azacitidine—Fatigue—Prednisone—systemic scleroderma	4.18e-05	0.000358	CcSEcCtD
Azacitidine—Discomfort—Methotrexate—systemic scleroderma	4.17e-05	0.000357	CcSEcCtD
Azacitidine—Constipation—Prednisone—systemic scleroderma	4.14e-05	0.000355	CcSEcCtD
Azacitidine—Confusional state—Methotrexate—systemic scleroderma	4.08e-05	0.00035	CcSEcCtD
Azacitidine—Anaphylactic shock—Methotrexate—systemic scleroderma	4.05e-05	0.000347	CcSEcCtD
Azacitidine—Infection—Methotrexate—systemic scleroderma	4.02e-05	0.000345	CcSEcCtD
Azacitidine—Feeling abnormal—Prednisone—systemic scleroderma	3.99e-05	0.000342	CcSEcCtD
Azacitidine—Nervous system disorder—Methotrexate—systemic scleroderma	3.97e-05	0.00034	CcSEcCtD
Azacitidine—Thrombocytopenia—Methotrexate—systemic scleroderma	3.96e-05	0.00034	CcSEcCtD
Azacitidine—Gastrointestinal pain—Prednisone—systemic scleroderma	3.96e-05	0.000339	CcSEcCtD
Azacitidine—Skin disorder—Methotrexate—systemic scleroderma	3.93e-05	0.000337	CcSEcCtD
Azacitidine—Hyperhidrosis—Methotrexate—systemic scleroderma	3.91e-05	0.000335	CcSEcCtD
Azacitidine—Anorexia—Methotrexate—systemic scleroderma	3.86e-05	0.000331	CcSEcCtD
Azacitidine—Urticaria—Prednisone—systemic scleroderma	3.85e-05	0.00033	CcSEcCtD
Azacitidine—Abdominal pain—Prednisone—systemic scleroderma	3.83e-05	0.000328	CcSEcCtD
Azacitidine—Body temperature increased—Prednisone—systemic scleroderma	3.83e-05	0.000328	CcSEcCtD
Azacitidine—Hypotension—Methotrexate—systemic scleroderma	3.78e-05	0.000324	CcSEcCtD
Azacitidine—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	3.69e-05	0.000316	CcSEcCtD
Azacitidine—Insomnia—Methotrexate—systemic scleroderma	3.66e-05	0.000314	CcSEcCtD
Azacitidine—Dyspnoea—Methotrexate—systemic scleroderma	3.61e-05	0.000309	CcSEcCtD
Azacitidine—Hypersensitivity—Prednisone—systemic scleroderma	3.57e-05	0.000306	CcSEcCtD
Azacitidine—Dyspepsia—Methotrexate—systemic scleroderma	3.56e-05	0.000305	CcSEcCtD
Azacitidine—Decreased appetite—Methotrexate—systemic scleroderma	3.52e-05	0.000301	CcSEcCtD
Azacitidine—Gastrointestinal disorder—Methotrexate—systemic scleroderma	3.49e-05	0.000299	CcSEcCtD
Azacitidine—Fatigue—Methotrexate—systemic scleroderma	3.49e-05	0.000299	CcSEcCtD
Azacitidine—Asthenia—Prednisone—systemic scleroderma	3.47e-05	0.000298	CcSEcCtD
Azacitidine—Pain—Methotrexate—systemic scleroderma	3.46e-05	0.000297	CcSEcCtD
Azacitidine—Pruritus—Prednisone—systemic scleroderma	3.43e-05	0.000294	CcSEcCtD
Azacitidine—Feeling abnormal—Methotrexate—systemic scleroderma	3.34e-05	0.000286	CcSEcCtD
Azacitidine—Diarrhoea—Prednisone—systemic scleroderma	3.31e-05	0.000284	CcSEcCtD
Azacitidine—Gastrointestinal pain—Methotrexate—systemic scleroderma	3.31e-05	0.000284	CcSEcCtD
Azacitidine—Urticaria—Methotrexate—systemic scleroderma	3.22e-05	0.000276	CcSEcCtD
Azacitidine—Dizziness—Prednisone—systemic scleroderma	3.2e-05	0.000274	CcSEcCtD
Azacitidine—Abdominal pain—Methotrexate—systemic scleroderma	3.2e-05	0.000274	CcSEcCtD
Azacitidine—Body temperature increased—Methotrexate—systemic scleroderma	3.2e-05	0.000274	CcSEcCtD
Azacitidine—Vomiting—Prednisone—systemic scleroderma	3.08e-05	0.000264	CcSEcCtD
Azacitidine—Rash—Prednisone—systemic scleroderma	3.05e-05	0.000262	CcSEcCtD
Azacitidine—Dermatitis—Prednisone—systemic scleroderma	3.05e-05	0.000261	CcSEcCtD
Azacitidine—Headache—Prednisone—systemic scleroderma	3.03e-05	0.00026	CcSEcCtD
Azacitidine—Hypersensitivity—Methotrexate—systemic scleroderma	2.98e-05	0.000256	CcSEcCtD
Azacitidine—Asthenia—Methotrexate—systemic scleroderma	2.9e-05	0.000249	CcSEcCtD
Azacitidine—Nausea—Prednisone—systemic scleroderma	2.88e-05	0.000246	CcSEcCtD
Azacitidine—Pruritus—Methotrexate—systemic scleroderma	2.86e-05	0.000245	CcSEcCtD
Azacitidine—Diarrhoea—Methotrexate—systemic scleroderma	2.77e-05	0.000237	CcSEcCtD
Azacitidine—Dizziness—Methotrexate—systemic scleroderma	2.68e-05	0.000229	CcSEcCtD
Azacitidine—Vomiting—Methotrexate—systemic scleroderma	2.57e-05	0.00022	CcSEcCtD
Azacitidine—Rash—Methotrexate—systemic scleroderma	2.55e-05	0.000219	CcSEcCtD
Azacitidine—Dermatitis—Methotrexate—systemic scleroderma	2.55e-05	0.000218	CcSEcCtD
Azacitidine—Headache—Methotrexate—systemic scleroderma	2.54e-05	0.000217	CcSEcCtD
Azacitidine—Nausea—Methotrexate—systemic scleroderma	2.4e-05	0.000206	CcSEcCtD
